X
InnoPharmax
About
About Us
Organization
Our History
News
News
Technologies
OralPAS®
OralPAS Pro®
MUCR™
R&D
Pipeline
D07001 GemOral
D0191801 Oral Insulin
D0282102 Bendamustine RTD
Products
Oncology Agents
Drugs for Rare Diseases
Anti-infection Agents
Contrast Agents
Immunological Agents
Active Pharmaceutical Ingredient
Investors
Financial Information
Company Profile
Monthly Revenue
Financial Statements
Corporate Governance
Board Meeting
Committee
Internal Audit
Rule of Procedure
Corporate Social Responsibility
Shareholders Services
Annual Reports
Shareholders' Meetings
Announcements
Contact
Contacts
Contact Information
Career Opportunities
中
News
2026/09/08
InnoPharmax Invites You to Follow CPHI 2026 in Milan from October 6 to October 8
2026/08/17
InnoPharmax Licensed Product Receives Marketing Authorization in Spain
2026/07/29
InnoPharmax Announces First Patient In for Global Phase 3 Trial of GemOral®(D07001) in the U.S.
2026/06/11
InnoPharmax’s official Linkedin page is now live
2026/06/05
Let’s meet at BIO2026, June 22-25 in San Diego!
More →
Vision and Strategy
Technologies
R&D
Products
uGear Design
-
Website Info.